Investors / United States / Aditum Bio
Aditum Bio
Venture capital · Oakland, CA, United States · North America
Aditum Bio is a biotech venture capital firm that forms and operates companies around acquired drug candidates. It focuses on the translation phase of drug development, advancing clinic-ready therapies into Phase 2 clinical trials through an in-house operating model.
Invests inHealthcare & Biotech
In its own wordsbiotechdrug developmenttherapeuticsclinical trialslife sciences
Your fit with Aditum Bio
Three questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAditum Bio lists 4 companies on its own site, 3 of them checked. It is named in 1 funding round. Its largest theme is Healthcare & Biotech (100%).
Counts come from funding rounds that name Aditum Bio, complete from mid-2025: earlier rounds appear only when they were reported later. Reports often leave out co-leads, so a firm may have led more rounds than shown. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage it came in at · n=0Counted only where the round is where it came in: a pre-seed or seed round, or a later round after the company raised without it. Aditum Bio does not state its stages on its site.
No round on record shows where Aditum Bio came in. Rounds are complete from mid-2025, so a later round may be a follow-on into a company it backed earlier; those are left out.
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 0 |
Investment themes
share of its 3 companies with a theme; a company can have twoThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 17% |
Shares portfolio companies with
firms that back the same companies, not always in the same roundShow as a table
| Share | |
|---|---|
| GV | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers3100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Compare Aditum Bio head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Team
22 people, as Aditum Bio's own site lists them- Joe JimenezCo-Founder and Managing Director
- Dr. Mark FishmanCo-Founder and Chair of the Scientific Advisory Board
- Praveena KandulaPrincipal
- Chris KleeOperating Partner
- Yousef BadranEntrepreneur-in-Residence
- Matthew Ambros
- Susie PhillipsExecutive Assistant
- Monica FinnController
- Hayden GrandeSr. Executive Assistant
- Mat LaFountainProcurement Manager
- Emily HealeyOperations Manager
- Tony DiBonaChief Financial Officer
Show all 22
- Brian Ridgeway
- Shyanne AliSVP Quality
- Chris Daige
- Ricardo Dolmetsch
- Matt Fitzpatrick
- Dr. Don GanemScientific Advisor
- sophie Hanscom
- Chamara Jayesinghe
- Denise Jones-Abud
- Scott PlevyHead of Immunology
Names and roles from this page of its site; VCinfo keeps nothing else about them. Listed here and want to be removed? Write to us.
Recent portfolio activity
when companies last raised with Aditum Bio| Date | Company | Stage |
|---|---|---|
| 25 Jun 2026 | Series B |
Round details for Aditum Bio
Amounts, full round histories and every co-investor in Aditum Bio's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
3 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Kalexo Bio is advancing dual-targeting siRNA therapeutics to address the most critical unmet needs in cardiovascular disease. | Healthcare & Biotech | Portfolio page | ||
| Oblenio Bio aims to transform the treatment of refractory autoimmune diseases | Healthcare & Biotech | Jun 2026Series B | Funding round | |
| Trames Bio is developing a new class of therapies designed to precisely and reversibly control neuronal activity to treat chronic pain | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- aditumbio.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 25 Jun 2026
- Companies checked
- 3
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Aditum Bio's profile as data
Pull Aditum Bio's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/aditumbio.com
# also
GET /v1/firms/aditumbio.com/portfolio
GET /v1/firms/aditumbio.com/coinvestors
GET /v1/firms/aditumbio.com/news